Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | PI4KA | P42356 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.33 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620238 | 1.00 | CHRNA7 (0.41) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3622692 | 0.92 | CHRNA7 (0.44) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3622695 | 0.92 | CHRNA7 (0.44) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3614227 | 0.80 | CHRNA7 (0.56) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3614230 | 0.80 | CHRNA7 (0.56) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3623477 | 0.80 | CHRNB2 (0.36) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3623480 | 0.80 | CHRNB2 (0.36) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3618118 | 0.80 | ADRA2A (0.35) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3618119 | 0.80 | ADRA2A (0.35) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3617444 | 0.79 | CHRNB2 (0.42) | CHRNA7CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8609662-B2 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases | NOVARTIS AG (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2457911-A1 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1776360-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | Novartis AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006005608-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885CHRNB4 13/4885CHRNA3 9/4885 |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB4 15/4885CHRNA3 6/4885 |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB4 15/4885CHRNA3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.